Challenges and opportunities in designing clinical trials for neuromyelitis optica - Wikidata - wikimedia - TriplyDB

Challenges and opportunities in designing clinical trials for neuromyelitis optica

Challenges and opportunities in designing clinical trials for neuromyelitis optica

http://www.wikidata.org/entity/Q26999708

about

Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders Placebo-controlled study in neuromyelitis optica-Ethical and design considerations Justification for conducting neurological clinical trials as part of patient care within private practice.Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations.Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.[Optical coherence tomography in neuromyelitis optica spectrum disorders].Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.

P2860

Q36484394-3E1A1F54-2970-4C9D-B8DA-BBE34C4C2EF4 Q36996492-D8EB3795-5F54-4E4C-BF8B-60550B03F942 Q38797002-C45B8166-DB22-4044-B636-0132BFA6EF3B Q38861682-758DF119-2887-466A-B143-E78A871A3E8F Q39692977-D8CDA25E-3D13-492A-B67F-E56D93FBE675 Q50101454-45A6D5ED-0718-4B1D-A63B-830CDB641752 Q52668258-9981059D-79AB-413A-8DD5-31F6CAA5D6D1

P2860

Challenges and opportunities in designing clinical trials for neuromyelitis optica

http://www.wikidata.org/entity/Q26999708

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@ast

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@en

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@nl

type

label

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@ast

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@en

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@nl

prefLabel

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@ast

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@en

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@nl

P1433

Q26999708-8254CFDA-A9B2-4D48-9DA2-3EDCC07C55D4

P1476

Q26999708-2797A128-B50A-4086-BC16-65ED9FDFD9BE

P2093

Q26999708-05A59456-16EA-42E6-9FC3-AF331FB31447

Q26999708-071E4081-BFE4-4F52-A8B2-0D70B82FD390

Q26999708-07F95AB3-7824-4BE0-A8C2-B4562DA74112

Q26999708-1248E666-80A8-44BA-9521-E2049A9D8BE6

Q26999708-16BA406D-2B96-46D4-AB55-380424EBD19B

Q26999708-205B0227-F84C-48B7-8255-46E668353E8B

Q26999708-2D8F9B83-603B-4045-8CD5-198A849895C0

Q26999708-2FBF902F-087E-47B8-94C9-11B6B2AD94B4

Q26999708-3661559C-F477-4FF5-AA88-BEA3F220C7BE

Q26999708-38307332-71B1-462F-A93D-5149C1548B56

P2860

Q26999708-005FD43F-411D-4175-BA2A-6600785FC169

Q26999708-00C5286D-D98A-4FAD-9A26-CC955D661725

Q26999708-14326CA4-0B78-4437-9A03-EDE2AF99B5FE

Q26999708-14432FE3-5B85-414D-AE0F-B28F436EDA0C

Q26999708-17E16AF7-909A-4EAD-A45B-3A39550C3C6D

Q26999708-1B4C8427-AA11-4BFB-8088-75B51F4C02BD

Q26999708-1BB91654-AC6D-48E3-B4BB-D2B8B945DBC8

Q26999708-1E90881E-B2BA-498B-AED6-5CD44183BDD6

Q26999708-1FC337BD-2701-4F0A-92F9-49FB83C6A0E2

Q26999708-215B0750-E1BD-489E-8A30-820905709CEA

P304

Q26999708-D8FBB3C7-47CE-46CE-B296-4A00DD7BF7AB

P31

Q26999708-510E2B6B-E5EF-4744-A2D3-47DEA0BADA6C

P3181

Q26999708-3EB2A1F3-9C8B-47A2-B7D1-E95080E37A46

P356

Q26999708-B86D6B41-214C-4FCA-9455-309A3762BC45

P407

Q26999708-1CF3D819-6BE2-4E65-AB29-AFE204333520

P433

Q26999708-BC0479FF-B325-4453-B5DF-6511002270D3

P478

Q26999708-5CFB8449-F189-414E-BED7-0C3C09BD0260

P50

Q26999708-DC36EFEB-CEAA-493B-B9A8-3B60EC30931E

Q26999708-E39BC4D5-06CF-4735-99CE-3E9DF0BB8A2F

P577

Q26999708-64392589-2F22-44E8-9DBD-1132F7AE009E

P698

Q26999708-1E77DABF-D4CF-4FE6-AB75-9517DA96629C

P921

Q26999708-3065C437-E058-43F3-8690-3BF93D7C2FB7

Q26999708-DFEF33FC-08F6-4528-9BA3-7ED8B5CD73B4

P932

Q26999708-27FF7AC5-FE27-4781-B14D-D159DCA550FC

P3181

P356

WNL.0000000000001520

P1433

P1476

Challenges and opportunities in designing clinical trials for neuromyelitis optica

@en

P2093

Angela T Melia

http://www.w3.org/2001/XMLSchema#string

Armando Flor

http://www.w3.org/2001/XMLSchema#string

Benjamin Greenberg

http://www.w3.org/2001/XMLSchema#string

Brian G Weinshenker

http://www.w3.org/2001/XMLSchema#string

Bruce A C Cree

http://www.w3.org/2001/XMLSchema#string

Dean M Wingerchuk

http://www.w3.org/2001/XMLSchema#string

Gerard Barron

http://www.w3.org/2001/XMLSchema#string

Guthy-Jackson Charitable Foundation International Clinical Consortium

http://www.w3.org/2001/XMLSchema#string

Jacinta M Behne

http://www.w3.org/2001/XMLSchema#string

Jacqueline Palace

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Postpartum misoprostol for preventing maternal mortality and morbidity

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy

Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

The clinical course of neuromyelitis optica (Devic's syndrome).

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

P304

1805-1815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1743870

http://www.w3.org/2001/XMLSchema#string

P356

10.1212/WNL.0000000000001520

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25841026

http://www.w3.org/2001/XMLSchema#string

P921

neuromyelitis optica

biomedical investigative technique

P932

4424131

http://www.w3.org/2001/XMLSchema#string